Morgan Cheatham, MD (@morgancheatham) header
Morgan Cheatham, MD (@morgancheatham) profile picture

investing in the future of biomedicine partner @BreyerCapital + medical geneticist @harvard editorial @NEJM_AI @decodingbio | bayesian

Brooklyn
Joined October 2016
Photo by Morgan Cheatham, MD (@morgancheatham)Photo by Morgan Cheatham, MD (@morgancheatham)Photo by Morgan Cheatham, MD (@morgancheatham)Photo by Morgan Cheatham, MD (@morgancheatham)Photo by Morgan Cheatham, MD (@morgancheatham)Photo by Morgan Cheatham, MD (@morgancheatham)Photo by Morgan Cheatham, MD (@morgancheatham)Photo by Morgan Cheatham, MD (@morgancheatham)Photo by Morgan Cheatham, MD (@morgancheatham)Photo by Morgan Cheatham, MD (@morgancheatham)
excited to share @breyercapital's latest healthcare thesis with my partner, @jimihendrixlive. healthcare is at an inflection point. scientific discovery is accelerating, but systems of translation remain structurally stagnant. the result is a widening chasm between what’s possible in principle and what’s practiced. we invest where scientific discovery, clinical necessity, and institutional transformation converge. computation, precision, and prevention are shaping the future of medicine, but only when anchored by economic models that reward long-term value. the next era of human health won’t be inherited. It will be engineered. if this vision resonates, we’d love to connect.
14
8
1
127
16,628
Morgan Cheatham, MD retweeted
“Cure is a big word.” I appreciated hearing my friend @VasNarasimhan's perspective on @CNBC with @SaraEisen in response to @DarioAmodei's prediction that AI could help cure diseases like cancer and Alzheimer's within the next decade. It raises an important question: what do we actually mean by a cure? Eradicating a disease altogether? Achieving a functional cure, with durable remission without ongoing treatment? Or transforming a life-threatening condition into a manageable chronic illness? Each would represent extraordinary progress, but these outcomes are not interchangeable. Vas offered an ambitious but more measurable vision: using AI to help reduce drug development timelines from roughly 12 years to eight, while increasing the proportion of drugs entering clinical trials that ultimately succeed from 8% to 12%. Those may sound like incremental improvements compared with curing all disease, but they would represent enormous advances for patients and the economics of drug development. I share Dario's optimism about what AI could unlock in biology and medicine. But we should be thoughtful about the expectations we create. Patients and families are listening. What sounds like an ambitious technological forecast can sound like a promise to someone waiting for a treatment. And scientific discovery is only part of the equation. Even if AI radically accelerates our ability to understand disease and develop new therapeutics, translating those discoveries into better patient outcomes requires coordination across clinical trials, regulators, manufacturers, clinicians, health systems, and payers. The last mile of medicine is not an afterthought. It's where scientific possibility becomes clinical reality. At Breyer Capital, we're excited to support companies working across this continuum, from fundamental discovery to clinical translation and care delivery. We should be unapologetically ambitious about what AI can make possible, while remaining equally rigorous about what it will take to deliver on that promise.
8
4
4
35
3,590
Morgan Cheatham, MD retweeted
Replying to @morgancheatham
direct-to-clinician never looked so good! four years after the initial "direct to clinician" thesis, physicians have spoken... morgancheatham.substack.com/…
1
2
6
1,083
direct-to-clinician never looked so good! four years after the initial "direct to clinician" thesis, physicians have spoken... morgancheatham.substack.com/…
Tuesday was the first day in OpenEvidence history with more than two million consults from verified U.S. clinicians in one 24-hour cycle. About one consult for every two physician office visits in America. The math: Americans make over a billion visits to physicians’ offices a year, roughly four million on a typical weekday. A consult is not a visit, and one visit can involve several questions. OpenEvidence is unequivocally the most popular AI for doctors in the United States and has become the default operating system of medical knowledge.
2
3
1
29
4,046
it's wild that in 2026, you can call a hospital and ask about a patient, only to be told with great confidence that "there's no patient by that name admitted at this hospital" but really the patient is in the emergency department, and the operator just can't see that list, so they tell you the patient doesn't exist
6
1
27
3,571
i’m interested in what AI does to “local medical information networks.” medicine is both an oral tradition and a science. some of it should become pure science. much of it will always be both. what makes a good clinician doesn’t come from reading papers alone. it comes from a thousand small exchanges: curbsides, asides on rounds, and the attending who has seen this presentation twice before and remembers exactly what went wrong. some of this AI can already reach, including the literature and “patients like mine” sitting in the EHR. the harder part is the tacit knowledge that lives in people: judgment, local practice, the case someone saw once and never wrote up. it’s also local to the patients we serve: their preferences, the communities they come from, the ways they present atypically. many patients are not in textbooks, or even in case reports. if a model answers first, do physicians call each other less? does AI slow knowledge transfer through local networks? or can it make them stronger? can it route me to the right colleague? can it capture what’s said on rounds without changing what people are willing to say? how do you encode knowledge that was never written down? now that access to the latest medical information is nearly free and instant, this is the next set of questions worth answering.
11
1
17
1,525
Morgan Cheatham, MD retweeted
New generation of docs + new generation of technology = new narrative
physician founders are on a tear this year. @Roche agreed to acquire Andrew Beck’s @Path_AI for up to $1.05B. @R1RCM acquired Jeremy Friese's Humata Health. yesterday, @ouraring agreed to acquire Muthu Alagappan's @CounselHealth for $625M in cash. the standard critique of physicians as founders is that "clinical training breeds caution." correlation isn’t causation, but what I take from these outcomes is that when AI makes knowledge free, there is a tremendous moat in hard-won human experience. never been a better time to be a physician founder.
1
2
24
2,653
one attribute of medical training that translates exceptionally well to being an entrepreneur: empirical decision-making acting on incomplete information, running the tests that close the gaps, and adjusting as the answers come in
physician founders are on a tear this year. @Roche agreed to acquire Andrew Beck’s @Path_AI for up to $1.05B. @R1RCM acquired Jeremy Friese's Humata Health. yesterday, @ouraring agreed to acquire Muthu Alagappan's @CounselHealth for $625M in cash. the standard critique of physicians as founders is that "clinical training breeds caution." correlation isn’t causation, but what I take from these outcomes is that when AI makes knowledge free, there is a tremendous moat in hard-won human experience. never been a better time to be a physician founder.
7
3
1
52
3,606
Morgan Cheatham, MD retweeted
When I’m on call, most of my work is a chart biopsy. What if a fellow was available around the clock to review the chart, present the patient, and help coordinate care? At The Conversation last month, we showed what that looks like: the @AbridgeHQ Assistant turning my goals into a plan, working across systems, and coming back when it needs my judgment. For me, the purpose is presence. Full attention on the patient, and confidence that the plan we make together gets carried through. We’ve talked about the Learning Health System for twenty years. We’re building it now with our partners. Full demo: abridge.com/blog/learning-he…
6
11
60
3,314
Morgan Cheatham, MD retweeted
So excited about this partnership @OpenEvidence and so proud to be an investor since 2022
“OpenEvidence is the most trusted and loved brand product among doctors. Apple is the most trusted and loved brand and product among consumers, and especially health consumers. So you have to bring these two things together. It’s like peanut butter and jelly.” --OpenEvidence CEO Daniel Nadler
3
3
65
7,226
Morgan Cheatham, MD retweeted
Today we are announcing our first clinical trial. We're joining forces with Prolong to evaluate a potential treatment for post exertional malaise (PEM) in #MECFS. Sanguinate is an investigational intravenous therapy designed to deliver oxygen to deprived tissues, support blood flow, and reduce inflammation. The planned multi-site Phase 2a trial will evaluate the drug in at least 40 patients with first dosing expected mid-2027. Most trials enroll patients based on symptoms alone, but recruitment for this study will leverage ChronicleBio's proprietary endotype intelligence platform to identify patients whose disease biology suggests they may be more likely to respond.  We are excited for our partnership with Prolong and grateful for the patient community that drives everything we do.  Read More: chroniclebio.com/news/chroni…
21
72
16
321
49,767
Morgan Cheatham, MD retweeted
And just like that, we have our first clinical trial and pharma partnership in the works! We’re teaming up with Prolong to take the drug they developed for stroke and see if it can help our patients with ME/CFS by increasing oxygen delivery and blood flow. Thanks to the 200TB of data @chroniclebioAI has amassed, combined with our AI engine, we are identifying patients that show hypoxia so we can focus this trial on them. This is really the promise of the company: understanding biology at such a deep level that we can match the exact right patients to the exact right drugs and massively increase the likelihood of success of trials. Going from company creation to first trial in less than two years is pretty cool, but there’s still a lot of work to be done to prove we can improve patients’ lives. One step at a time.
Today we are announcing our first clinical trial. We're joining forces with Prolong to evaluate a potential treatment for post exertional malaise (PEM) in #MECFS. Sanguinate is an investigational intravenous therapy designed to deliver oxygen to deprived tissues, support blood flow, and reduce inflammation. The planned multi-site Phase 2a trial will evaluate the drug in at least 40 patients with first dosing expected mid-2027. Most trials enroll patients based on symptoms alone, but recruitment for this study will leverage ChronicleBio's proprietary endotype intelligence platform to identify patients whose disease biology suggests they may be more likely to respond.  We are excited for our partnership with Prolong and grateful for the patient community that drives everything we do.  Read More: chroniclebio.com/news/chroni…
81
109
18
876
81,275
excited to take this for a spin at the bedside AlphaGenome 2 plus @OpenEvidence could unlock scalable variant interpretation at the point of care
Super proud to announce AlphaGenome 2 - our new DNA sequence model! 🧬 It predicts the impact of DNA variants in different specific cell types - unlocking crucial information for understanding complex diseases. Available for academic research via our API: alphagenomedocs.com/
1
1
18
1,594
Morgan Cheatham, MD retweeted
For years, I’ve recommended @nvidia to founders, partners, and fellow investors. The technical moat, product velocity, and market execution that @JensenHuang and his team have built over three decades set a new standard for modern technology leadership. My conviction dates back many years. At Davos in January 2019, when @nvidia was trading around $3.50 per share, split-adjusted, I told @CNBC that I loved NVIDIA for the long term. I also predicted that AI-first companies would eventually dominate the ranks of the world’s largest companies. In 2021, I emphasized the significant technological lead held by NVIDIA and America's leading semiconductor companies. In 2022, I said, “NVIDIA is so far ahead of everyone else… I love NVIDIA.” In 2023, I described NVIDIA as looking “unstoppable over the next three years.” And in 2024, I reiterated: “I’ve been pounding the table on NVIDIA… I still am.” Over the past six years, I've had the privilege of learning an enormous amount from Jensen and his extraordinary team at NVIDIA. I've also learned so much from @LisaSu, a good friend, and her remarkable team at @AMD. Both companies are testaments to the extraordinary innovation and technological leadership of the American semiconductor industry. Through every stage of the AI revolution, my conviction in NVIDIA and its leadership has remained unwavering. And yet, even with that conviction, I never could have anticipated a moment like this. It is a powerful reminder that investing, regardless of financial performance, remains a deeply person-centered business. Behind every extraordinary company are extraordinary people, relationships, and decades of hard work. It is always humbling. @SaraEisen, @andrewrsorkin, @BeckyQuick
16
7
1
109
11,155
science, capital, and conviction rarely arrive at the same time. today at the Decoding Bio Investor Summit, i’ll be speaking with Tim Springer and Arjun Goyal about how biotech breakthroughs translate from the lab to the market. after decades of pioneering integrin biology, Tim founded companies including LeukoSite, Scholar Rock, and Morphic (acquired by Lilly for $3.2B), and cofounded Moderna and Editas. Arjun, a physician by training, cofounded Vida Ventures and helped build it into a roughly $2B life sciences firm before launching Vianti Capital. stop by if you’ll be there!
1
26
1,508
physician founders are on a tear this year. @Roche agreed to acquire Andrew Beck’s @Path_AI for up to $1.05B. @R1RCM acquired Jeremy Friese's Humata Health. yesterday, @ouraring agreed to acquire Muthu Alagappan's @CounselHealth for $625M in cash. the standard critique of physicians as founders is that "clinical training breeds caution." correlation isn’t causation, but what I take from these outcomes is that when AI makes knowledge free, there is a tremendous moat in hard-won human experience. never been a better time to be a physician founder.
18
14
4
197
17,807
the amazing run for physician-founded healthcare AI companies continues. congrats to Muthu and the Counsel Health team!
Today, we're excited to announce that Counsel is being acquired by @ouraring, bringing together our shared visions for the future of healthcare. Three years ago, we founded Counsel to reimagine primary care through the lens of AI and to embark on a mission to multiply the world’s clinical capacity.
2
32
1,887
Morgan Cheatham, MD retweeted
We first backed @shieldaitech at the Series A in 2018, when the bet was that autonomy would transform defense. Today Shield announced a $5.3B acquisition of @EchodyneCorp and a Series H financing round at a $28.8B valuation. Congratulations to @garylsteele, Eben Frankenberg, @rtsengusa, and @brandontseng2 .
3
2
1
41
4,401
amazing product launch today from @OpenEvidence for all the lifelong learners in medicine 📙
Introducing Learn, a free, personalized medical education platform from OpenEvidence, built to support trainees and clinicians across their entire careers. As AI changes how doctors work, it matters just as much that it strengthens how they learn. Clinicians have made OpenEvidence an everyday tool at the point of care. Now we apply that same technology and those same principles to how doctors learn medicine. Developed with leading medical institutions, certifiers, and educators, Learn brings together a suite of tools built on OpenEvidence so every trainee and clinician gets a tailored, evidence-based learning experience.
3
16
202
18,788
Morgan Cheatham, MD retweeted
CNN PROJECTS THAT THE MITOCHONDRIA WILL REMAIN THE POWERHOUSE OF THE CELL
177
5,866
215
54,490
1,110,118
Morgan Cheatham, MD retweeted
🚨Introducing the SAIL Therapeutic Actionability AI Challenge🚨 ~450M people have a rare disease, often facing decades-long journeys to find therapies. <10% of rare diseases have an FDA-approved one. We think AI can help close this gap. Submit your model by Jan 5. Details 👇
19
16
2
52
6,299